Investigation of the effectiveness of whole wheat bread intake for 12 weeks against metabolic syndrome index: Effects on visceral fat area, fasting blood glucose and serum lipids.

Investigation of the effectiveness of whole wheat bread intake for 12 weeks against metabolic syndrome index: Effects on visceral fat area, fasting blood glucose and serum lipids. - Investigation of the effectiveness of whole wheat bread intake for 12 weeks against metabolic syndrome index.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018673

Enrollment

Registered

2015-08-20

Start date

2015-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects ( BMI &gt

Interventions

Intake of approximately 100 grams of whole wheat bread twice a day for 12 weeks. Intake of approximately 100 grams of wheat flour bread twice a day for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Aged between 20 and 64 years old at consent. (2) BMI >= 23.0 kg/m2 (3) Subjects who understand the study procedures and agree to participate in the study by giving informed consent prior to the study.

Exclusion criteria

Exclusion criteria: (1) Subjects who have continuous intake of Divaricate Saposhnikovia Miraculous Powder. (2) Subjects who take drugs to treat dyslipidemia. (3) Subjects who experienced body weight changes >= 10% within a year before the start date of this study. (4) Fasting blood glucose >=126 mg/dl or HbA1c (NGSP) >=6.5% or diabetic patient. (5) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ). (6) Subjects who have history of surgery in gastrointestinal tract. (7) Subjects who have history of malignant diseases. (8) Females who are pregnant or lactating, and who could become pregnant or lactating during test period. (9) Subjects who have excessive alcohol intake. (10) Subjects who have extremely irregular dining habits, and who have midnight work or irregular shift work. (11) Subjects who have continuous intake of dietary fiber supplement or whole grain. (12) Subjects who have serious infectious diseases. (13) Subjects who have previous medical history of drug and/or food allergy. (14) Subjects who are participating in other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate in other clinical tests. (15) Subjects who donated over 200mL blood and/or blood components within the last one month. (16) Males who donated over 400mL blood within the last three month. (17) Females who donated over 400mL blood within the last four month. (18) Males who will be collected over 1200 mL of blood when the planned sampling volume in this study is added to the volume collected within the last 12 months. (19) Females who will be collected over 800 mL of blood when the planned sampling volume in this study is added to the volume collected within the last 12 months. (20) Subjects who are not eligible for this study for some medical reasons.

Design outcomes

Primary

Measure	Time frame
metabolic syndrome index (visceral fat area, serum lipids) It will be measured at week 0, 6, and 12.	—

Secondary

Measure	Time frame
Blood HbA1c, serum insulin, leptin, adiponectin levels, fasting blood glucose, blood pressure	—

Countries

Japan

Contacts

Public ContactMakoto Ichinohe

CPCC Company Limited Plan Sales Department

m.i@cpcc.co.jp03-5297-3112

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026